Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Sternberg

Showing results (441-450 of 564) with videos related to

Pageof 57
Sort By:
Targeted Oncology|January 7, 2015
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapyMatteo Santoni, Sebastiano Buti, Alessandro Conti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2019
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with NivolumabUgo De Giorgi, Giuseppe Procopio, Diana Giannarelli, et al.
Molecular Oncology|March 1, 2022
The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapyJohannes C van der Mijn, Kenneth W Eng, Pooja Chandra, et al.
ESMO Open|May 13, 2021
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohortG Fornarini, S E Rebuzzi, G L Banna, et al.
European Urology|March 24, 2016
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerChristopher P Evans, Celestia S Higano, Thomas Keane, et al.
European Urology|July 18, 2021
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD StudyCora N Sternberg, Daniel Castellano, Johann de Bono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trialRobert J Motzer, Dmitry Nosov, Timothy Eisen, et al.
European Urology|June 4, 2025
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only DiseaseJoaquim Bellmunt, Thomas Powles, Se Hoon Park, et al.
European Journal of Cancer (Oxford, England : 1990)|June 30, 2026
Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trialKarim Fizazi, Matthew R Smith, Maha Hussain, et al.
European Urology|April 30, 2023
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 TrialPetros Grivas, Se Hoon Park, Eric Voog, et al.
Pageof 57

Showing results (441-450 of 564) with videos related to

Sort By:
Pageof 57
Targeted Oncology|January 7, 2015
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapyMatteo Santoni, Sebastiano Buti, Alessandro Conti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2019
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with NivolumabUgo De Giorgi, Giuseppe Procopio, Diana Giannarelli, et al.
Molecular Oncology|March 1, 2022
The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapyJohannes C van der Mijn, Kenneth W Eng, Pooja Chandra, et al.
ESMO Open|May 13, 2021
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohortG Fornarini, S E Rebuzzi, G L Banna, et al.
European Urology|March 24, 2016
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerChristopher P Evans, Celestia S Higano, Thomas Keane, et al.
European Urology|July 18, 2021
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD StudyCora N Sternberg, Daniel Castellano, Johann de Bono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trialRobert J Motzer, Dmitry Nosov, Timothy Eisen, et al.
European Urology|June 4, 2025
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only DiseaseJoaquim Bellmunt, Thomas Powles, Se Hoon Park, et al.
European Journal of Cancer (Oxford, England : 1990)|June 30, 2026
Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trialKarim Fizazi, Matthew R Smith, Maha Hussain, et al.
European Urology|April 30, 2023
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 TrialPetros Grivas, Se Hoon Park, Eric Voog, et al.
Pageof 57